Low dose docetaxel chemotherapy for castration-resistant prostate cancer Tomoyuki Tatenuma 1 , Ryoko Sakata 1 , Shinpei Sugiura 1 , Takehiro Tajiri 1 , Kazuo Kitami 1 1Department of Urology, Fujisawa City Hospital Keyword: 去勢抵抗性前立腺癌 pp.427-431
Published Date 2013/5/20
DOI https://doi.org/10.11477/mf.1413103218
  • Abstract
  • Look Inside
  • Reference

We treated 27 patients of castration resistant prostate cancer(CRPC)with low-dose docetaxel(DCT)in our hospital. The efficacy and safety were evaluated. DCT was given at a dose of 25 mg/m2 on days 1 and 8 every 3 weeks. The patients were from 54 to 84 years old(median 69). PSA value before DCT treatment was from 1.005 to 1,710 ng/ml(median 28.1). Patients received a median of ten cycles(range:0-49). PSA decreased in 21 patients(84%). PSA decrement greater than 50% was seen in 13(52%). Median time to progression and overall survival was 8.7 and 27.6 months, respectively. Grade 3-4 myelosuppression was observed in only one patient(4%). Low-dose DCT therapy is an effective and well tolerated treatment for CRPC patients.

Copyright © 2013, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1332 印刷版ISSN 0385-2393 医学書院